---
title: Pharma Case Study
---

[Skip to content](https://www.attaima.com/-cs-1#main-content)

[![attaima-logo](https://www.attaima.com/hubfs/attaima-logo.svg) ![attaima logo](https://www.attaima.com/hubfs/attaima-logo.svg)](https://www.attaima.com?hsLang=en)

[Contact our Team](https://www.attaima.com/contact-attaima?hsLang=en)

- [Home](https://www.attaima.com)
- [Product](https://www.attaima.com/attaima-product)
- [Tech](https://www.attaima.com/attaima-tech)
- [Industries](https://www.attaima.com/industries)
- [About](https://www.attaima.com/about-attaima)
- [FAQ](https://www.attaima.com/attaima-faq)
- [Careers](https://www.attaima.com/attaima-careersx)

##### Case Study

# Pharmaceutical Supply Chain Risk

#### From Hidden Dependencies to Defensible, Revenue-Protected Decisions

Mapped 300+ suppliers across 4 tiers in under 3 days—identifying critical single points of failure and quantifying nine-figure revenue exposure.

 

### Client Challenge

#### A Fortune 500 pharmaceutical manufacturer experienced a critical supplier disruption that resulted in significant revenue loss for a key product line and weakened its competitive position in regulated markets.

![pharma-2](https://www.attaima.com/hubfs/pharma-2.jpg)

Despite operating in a highly controlled environment, **critical dependencies beyond tier 1 were not fully visible**, leaving the organisation exposed to:

- Single points of failure across APIs and components 
- Long supplier replacement cycles due to regulatory constraints 
- Inability to respond quickly to disruptions
- Loss of market share during supply shortages 

Investigations were **slow, resource-intensive, and heavily reliant on manual processes**, often taking weeks or months to fully assess impact.

At the executive level, there was **no clear, defensible link between supply chain disruption and revenue impact**, limiting the ability to act with confidence or justify mitigation decisions.

#### Scope and Objectives

**Goal:** Rapidly discover, visualize, and mitigate supply chain risks across two high-value product lines—while quantifying financial exposure and improving audit readiness.

**Key Inputs**

- Bills of Materials (BOMs) for two products
- Partial list of global operating sites
- Partial tier 1 supplier data

 

##### Case Study

## The Approach

 

##### 1. Discover & Visualize

- Ingested BOMs and supplier data to map **tier 1 through tier 4 suppliers and dependencies**
- Inferred production geographies and supply flows across regulated components
- Delivered a live, user-friendly, human-centric interactive canvas of the full value chain

![pharma-cs-1](https://www.attaima.com/hubfs/pharma-cs-1.svg)

 

##### 2. Identify Weak Spots

- Highlighted **single points of failure and supplier concentration risks**
- Enriched supplier network with **financial, geographic, and operational risk indicators**
- Identified **critical vulnerabilities across APIs and regulated inputs**
- Quantified **potential revenue exposure tied to key nodes** 

![pharma-cs-2-1](https://www.attaima.com/hubfs/pharma-cs-2-1.svg)

 

##### 3. Mitigate

- Surfaced **similarly qualified alternative suppliers **
- Enabled **data-driven mitigation strategies aligned with regulatory and recertification constraints **
- Supported faster decision-making on **supplier replacement and diversification**  

![pharma-cs-3](https://www.attaima.com/hubfs/pharma-cs-3.svg)

 

##### Outcomes

- End-to-end visibility across 300+ entities spanning multiple tiers 
- Identification of critical vulnerabilities and single points of failure 
- Quantified >€100M revenue exposure linked to key dependencies
- Reduced time to impact assessment from ~6–8 weeks to <5 days
- Improved ability to make audit-ready, defensible sourcing decisions 

 

#### **Why Attaima?**

- **Speed at scale:** Delivered multi-tier visibility in days, not months
- **Deep tier insight:** Uncovered dependencies beyond tier 1 in regulated environments
- **Financial linkage:** Connected supply chain disruption directly to revenue impact
- **Regulatory-ready:** Supported compliant, defensible decision-making
- **Continuous monitoring:** Enabled early detection of emerging risks

#### **Next steps / ongoing work**

- Expand coverage across additional product lines and global operations
- Integrate **continuous monitoring across suppliers and geographies**
- Enhance **scenario modelling to simulate disruption and mitigation strategies**

![pharma-white](https://www.attaima.com/hubfs/pharma-white.svg)

> " We moved from reactive investigations to proactive, financially grounded decision-making across our supply chain. "

##### – Global Supply Chain Leader

###### Pharmaceutical Manufacturer

## ![Emblem](https://www.attaima.com/hs-fs/hubfs/Emblem.png?width=40&height=37&name=Emblem.png)

## Learn more about how attaima can help your pharma value chain

[![attaima-logo](https://www.attaima.com/hubfs/attaima-logo.svg)](https://www.attaima.com?hsLang=en)

- [Terms & Conditions](https://www.attaima.com/attaima-terms-conditions)
- [Privacy Policy](https://www.attaima.com/attaima-privavcy-policy)

© 2026 Attaima | All rights reserved.